In this Pharmaceutical Executive exclusive, Bob Jansen, David Shulkin, Gen. Paul Funk (Ret.), and Maj. Gen. Dennis LeMaster ...

Mercalis and PharmaCord announced the completion of their merger. The new company is rebranding itself as Valeris, which will ...

Pharmaceutical Executive: What are the factors that are impacting the compounded semaglutide market? Ferrin Williams, PharmD: ...

Clearance of ASC50 paves the way for a Phase I trial in patients with mild-to-moderate plaque psoriasis.

Deal includes VG-3927, a first-in-class TREM2 agonist aimed at advancing next-generation Alzheimer disease therapies.

Positive feedback was based on Phase III AQUILA trial results, which showed a significant clinical benefit with Darzalex ...

As the FDA’s ban on mass compounding of semaglutide takes effect, Novo Nordisk introduces discounted pricing and new patient ...

The FDA has approved Roche’s Susvimo (ranibizumab injection) 100 mg/mL for treating patients with diabetic retinopathy (DR).

Lilly is also developing oral therapies for its gastroenterology pipeline.

SK Life Science launched its latest DTC advertising campaign for its seizure medication. 1 Road to Reduction is an ...

Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil ...

Prioritizing deeper customer insights helps life sciences marketers understand how to engage their HCP audiences effectively ...